Alpine Immune Sc Stock Price, News & Analysis

Alpine Immune Sciences, Inc. (NASDAQ: ALPN) announced its participation in two major investor conferences in January 2022. The company will present at the H.C. Wainwright BIOCONNECT Virtual Conference on January 10, 2022, available on demand from 7:00 a.m. ET. The second event is the J.P. Morgan Healthcare Conference on January 13, 2022, at 12:00 p.m. ET. Webcasts will be accessible on the company’s investor relations webpage for 90 days. Alpine focuses on developing innovative immunotherapies for cancer and autoimmune diseases.

Horizon Therapeutics and Alpine Immune Sciences have announced an exclusive licensing agreement for the development of up to four preclinical candidates. Horizon will pay $40 million upfront, with the potential for Alpine to earn up to $1.52 billion in milestone and royalty payments. The collaboration aims to merge Alpine's discovery platform with Horizon's development capabilities, particularly for autoimmune and inflammatory diseases. This partnership marks a significant expansion of Horizon's preclinical pipeline.

Alpine Immune Sciences, Inc. (NASDAQ: ALPN) will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on December 1, 2021, at 12:35 p.m. ET. The event will be accessible via a live webcast on the company's investor relations page, with a replay available for 90 days post-event. Alpine focuses on developing innovative immunotherapies for cancer and autoimmune diseases, leveraging advanced protein engineering technologies. Collaborations with global biopharmaceutical companies enhance their diverse pipeline of clinical and preclinical candidates.

Alpine Immune Sciences (NASDAQ: ALPN) reported significant progress in Q3 2021, including a $91M securities offering to enhance developmental efforts. The company aims to accelerate the clinical evaluation of ALPN-303 and ALPN-202, with the former's phase 1 study set to begin by year-end 2021. ALPN-303 data showcased its potential during the ACR Convergence 2021 Annual Meeting. Financially, ALPN reported net losses of $13.5M with collaboration revenue rising to $8.5M, largely due to the AbbVie Agreement. Cash reserves are projected to sustain operations through 2023.

Alpine Immune Sciences (NASDAQ: ALPN) presented promising data on ALPN-303, an engineered dual BAFF/APRIL inhibitor, at the ACR Convergence 2021 meeting. The preclinical study shows that ALPN-303 exhibits over 5-fold greater potency than wild-type TACI-Fc in inhibiting B cell cytokines. Results from animal models indicate that it effectively reduces harmful B cell populations while improving renal function in lupus models. A Phase 1 clinical trial for healthy adults is set to begin in Q4 2021, aiming to evaluate the safety and efficacy of ALPN-303.

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) has announced a definitive securities purchase agreement, raising approximately $91 million through a private placement of common stock and prefunded warrants. The placement, led by Frazier Life Sciences Public Fund, will issue around 6.5 million shares at $9.40 each, a 4.4% premium over the previous closing price. Proceeds will support the development of ALPN-303 and ALPN-202. The closing is expected on September 17, 2021, pending customary conditions.

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) will present at several investor conferences in September 2021. Key events include the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, Oppenheimer Fall Healthcare Summit on September 20, and Cantor Global Healthcare Conference on September 29. Each presentation will be available via webcast on the company's investor relations website. Alpine is focused on innovative immunotherapy treatments for cancer and autoimmune diseases, emphasizing collaborations and a diverse pipeline.

Alpine Immune Sciences, a clinical-stage immunotherapy firm, reported a productive second quarter with significant milestones. Key highlights include the initiation of the Synergy Phase 2 trial of acazicolcept in lupus patients, achieving $45 million in development milestones with AbbVie, and presenting promising data on ALPN-202 at ASCO 2021. The firm had cash resources of $100.4 million as of June 30, 2021, and expects to fund operations through 2023. The company remains on track to initiate Phase 1 for ALPN-303 in Q4 2021, reinforcing its strong pipeline in immunology and oncology.

Alpine Immune Sciences (NASDAQ:ALPN) will release its second quarter 2021 financial results on August 10, 2021, after market close. A conference call and webcast will be held at 4:30 p.m. ET to discuss the results and provide a corporate update. Additionally, the company will participate in the Bernstein CD28 Day on August 9 and the Wedbush PacGrow Healthcare Virtual Conference on August 11. The company focuses on developing innovative immunotherapies for cancer and autoimmune diseases, supported by strategic collaborations and a diverse pipeline.